- Home
- MIN vs FHTX Comparison
MIN vs FHTX Comparison
Compare MIN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- FHTX
- Stock Information
- Founded
- MIN 1988
- FHTX 2015
- Country
- MIN United States
- FHTX United States
- Employees
- MIN N/A
- FHTX N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- MIN Finance
- FHTX Health Care
- Exchange
- MIN Nasdaq
- FHTX Nasdaq
- Market Cap
- MIN 310.1M
- FHTX 517.9M
- IPO Year
- MIN N/A
- FHTX 2020
- Fundamental
- Price
- MIN $2.72
- FHTX $7.55
- Analyst Decision
- MIN
- FHTX Strong Buy
- Analyst Count
- MIN 0
- FHTX 5
- Target Price
- MIN N/A
- FHTX $16.00
- AVG Volume (30 Days)
- MIN 331.0K
- FHTX 135.3K
- Earning Date
- MIN 01-01-0001
- FHTX 11-04-2024
- Dividend Yield
- MIN 7.31%
- FHTX N/A
- EPS Growth
- MIN N/A
- FHTX N/A
- EPS
- MIN 0.08
- FHTX N/A
- Revenue
- MIN N/A
- FHTX $35,185,000.00
- Revenue This Year
- MIN N/A
- FHTX N/A
- Revenue Next Year
- MIN N/A
- FHTX $15.40
- P/E Ratio
- MIN $33.38
- FHTX N/A
- Revenue Growth
- MIN N/A
- FHTX 61.95
- 52 Week Low
- MIN $2.52
- FHTX $2.70
- 52 Week High
- MIN $2.88
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- MIN 44.73
- FHTX 45.26
- Support Level
- MIN $2.70
- FHTX $7.24
- Resistance Level
- MIN $2.74
- FHTX $8.35
- Average True Range (ATR)
- MIN 0.02
- FHTX 0.54
- MACD
- MIN -0.00
- FHTX -0.06
- Stochastic Oscillator
- MIN 22.89
- FHTX 43.20
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.